hVIVO PLC

CRO

Company Profile

  • Business description

    hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which is involved in the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences’ Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.

  • Contact

    40 Bank Street
    Floor 24
    LondonE14 5NR
    GBR

    E: [email protected]

    https://www.hvivo.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    299

Stocks News & Analysis

stocks

Undervalued ASX income play

Major development projects remain on schedule.
stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

With the monetization of GenAI, here’s what we think of Alphabet’s stock
stocks

Going into earnings, Is Meta stock a buy, a sell, or fairly valued?

With a focus on leveraging its AI investments, here’s what we think of Meta stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.5015.300.17%
CAC 407,738.3059.92-0.77%
DAX 4024,048.74259.06-1.07%
Dow JONES (US)44,323.0719.12-0.04%
FTSE 1008,996.5216.47-0.18%
HKSE25,130.03135.890.54%
NASDAQ20,974.1878.520.38%
Nikkei 22539,774.9244.19-0.11%
NZX 50 Index12,833.74127.77-0.99%
S&P 5006,305.600.000.00%
S&P/ASX 2008,677.209.000.10%
SSE Composite Index3,581.8622.070.62%

Market Movers